Marco Davila, MD, PhD, on Investigating Mechanisms of CAR T Resistance in B-cell Malignancies


The vice chair for cellular therapies at Roswell Park Comprehensive Cancer Center discussed new research from the center presented at the 2023 Tandem Meetings.

“CAR T cells were first approved for patients with B-cell malignancies in 2017. We've seen tremendous outcomes for these patients, up to 30 to 40% of patients have long term remissions. But that also means that the majority of patients don't have long term remissions. And what we're trying to do is utilize samples from patients to understand what mechanisms might be behind those nonresponses or early relapses.”

Research remains to be done to understand more about what characteristics and mechanisms lead to some patients with B-cell malignancies to have durable responses to chimeric antigen receptor (CAR) T-cell therapies while others do not respond or relapse early. Investigators at Roswell Comprehensive Cancer Center, including Marco Davila, MD, PhD, Senior Vice President and Associate Director, Translational Research, and Vice-Chair, Cellular Therapies.

Davila presented research him and his colleagues are conducting at the center to address the question of CAR T resistance at the 2023 Tandem Meetings |Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, held in Orlando, Florida, February 15-19, 2023. CGTLive spoke with Davila to learn more about the unmet needs in this area of research and some findings that were presented.

Davila ML. Mechanisms of Resistance to CD19-Targeted CAR T Cells: Lessons from Mice and Patients. Presented at: 2023 Tandem Meetings, February 15-19, 2023.
Related Videos
George Tachas, PhD, on Tackling DMD Treatment From Multiple Angles
David Suhy, PhD, the cofounder and chief scientific officer of Earli
Deepak L. Bhatt, MD, MPH, MBA, on Incorporating AI into Genetic Research for Cardiovascular Disease
Jeffrey Chamberlain, PhD, on Helping Progress Cell and Gene Therapy Development
Jonathan W. Weinsaft, MD, on Integrating Genetic Research into Cardiovascular Medicine
Jacques Galipeau, MD, on Highlights from ISCT 2024’s Presidential Plenary
Vanee Pho, PhD, the senior director of product management, cell and gene therapy, at Mission Bio
Michael Wang, MD, a professor in the Department of Lymphoma/Myeloma at MD Anderson Cancer Center
Robert J. Hopkin, MD, on Looking Deeper into Fabry Disease Biology
Steven W. Pipe, MD, on Confirming Efficacy, Safety of Hemgenix Gene Therapy in Hemophilia B Populations
© 2024 MJH Life Sciences

All rights reserved.